Safety and Short-term Efficacy of Mirabegron in Children with Valve Bladder: a Pilot Study

Overview

Journal Pediatr Surg Int

Specialties General Surgery
Pediatrics

Date 2021 Dec 3

PMID 34859277

Citations 1

Authors

Ramesh Babu

Thiyagarajan Chittibabu

Sugandh Chadha

Affiliations

Soon will be listed here.

Abstract

Aims: This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV).

Methods: Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5-1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy.

Results: There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects.

Conclusion: This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.

Citing Articles

Re: Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study.

Deng C, Chen Y, Dai R Pediatr Surg Int. 2022; 38(6):949-950.

PMID: 35362797 DOI: 10.1007/s00383-022-05120-3.

References

Jaureguizar E, Lopez-Pereira P . The valve bladder: etiology and outcome. Curr Urol Rep. 2002; 3(2):115-20. DOI: 10.1007/s11934-002-0021-8. View

Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016; 70(1):9-13. DOI: 10.1016/j.eururo.2016.02.007. View

Fryer S, Nicoara C, Dobson E, Griffiths M, McAndrew H, Kenny S . Effectiveness and tolerability of mirabegron in children with overactive bladder: A retrospective pilot study. J Pediatr Surg. 2019; 55(2):316-318. DOI: 10.1016/j.jpedsurg.2019.10.044. View

Tessi C, Szklarz M, Imizcoz F, Ruiz J, Weller S, Sager C . Simultaneous bilateral endoscopic surgery in a pediatric patient: Description of a NOVEL technique. J Pediatr Urol. 2020; 17(1):117-118. DOI: 10.1016/j.jpurol.2020.11.042. View

Park J, Lee Y, Lee C, Kim S, Kim S, Han S . Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2018; 37(8):1665-1670. DOI: 10.1007/s00345-018-2576-0. View

Futyma K, Nowakowski L, Bogusiewicz M, Zietek A, Wieczorek A, Rechberger T . Use of uroflow parameters in diagnosing an overactive bladder-Back to the drawing board. Neurourol Urodyn. 2015; 36(1):198-202. DOI: 10.1002/nau.22898. View

Bauer S, Dieppa R, Labib K, Retik A . The bladder in boys with posterior urethral valves: a urodynamic assessment. J Urol. 1979; 121(6):769-73. DOI: 10.1016/s0022-5347(17)56985-2. View

DUCKETT J . Are 'valve bladders' congenital or iatrogenic?. Br J Urol. 1997; 79(2):271-5. DOI: 10.1046/j.1464-410x.1997.26922.x. View

Mitchell M, Close C . Early primary valve ablation for posterior urethral valves. Semin Pediatr Surg. 1996; 5(1):66-71. View

10.

Koff S, Mutabagani K, Jayanthi V . The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. J Urol. 2001; 167(1):291-7. DOI: 10.1016/s0022-5347(05)65453-5. View

11.

Abraham M, Nasir A, Sudarsanan B, Puzhankara R, Kedari P, Unnithan G . Role of alpha adrenergic blocker in the management of posterior urethral valves. Pediatr Surg Int. 2009; 25(12):1113-5. DOI: 10.1007/s00383-009-2469-9. View

12.

Casey J, Hagerty J, Maizels M, Chaviano A, Yerkes E, Lindgren B . Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol. 2012; 188(4 Suppl):1516-20. DOI: 10.1016/j.juro.2012.03.068. View

13.

Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M . Double anticholinergic therapy for refractory overactive bladder. J Urol. 2009; 182(4 Suppl):2033-8. DOI: 10.1016/j.juro.2009.05.099. View

14.

Morin F, Blais A, Nadeau G, Moore K, Genois L, Bolduc S . Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2016; 197(4):1158-1163. DOI: 10.1016/j.juro.2016.11.101. View